Physician profile
Mark Garcia
NPI 1447278262
$2,046.13
in general payments reported to CMS, 2019-2025
21 companies · $443 in 2025
The $443 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $295 · 2021: $376 · 2022: $95.15 · 2023: $127 · 2024: $297 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $645 · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $644.57 |
| Education | $222.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $464.76 | 2019-2024 | |
| Janssen Biotech, INC. | $450.34 | 2019-2025 | Tremfya |
| Galderma Laboratories, L.P. | $178.28 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $145.85 | 2019-2025 | |
| Pfizer INC. | $134.73 | 2019-2025 | |
| Lilly USA, LLC | $126.66 | 2021 | |
| Astellas Pharma US INC | $99.00 | 2024 | |
| Ucb, INC. | $94.58 | 2021-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $88.29 | 2023-2025 | Sotyktu |
| Amgen INC. | $44.04 | 2021-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $33.98 | 2022 | |
| Leo Pharma INC. | $30.98 | 2023-2025 | Anzupgo, Adbry |
| Allergan, INC. | $26.16 | 2021 | |
| Kyowa Kirin, INC. | $23.50 | 2023 | Poteligeo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.96 | 2025 | Siliq, Jublia, Cabtreo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $18.92 | 2021 | |
| Mylan Pharmaceuticals INC. | $17.62 | 2019 | |
| Pharmacosmos Therapeutics INC. | $15.08 | 2021 | |
| Merck Sharp & Dohme LLC | $12.30 | 2019 | |
| Genentech USA, INC. | $11.81 | 2019 | |
| Mayne Pharma Commercial LLC | $6.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.